SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Kaposi Sarcoma
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
Discussion Leader
Thomas S. Uldrick
National Cancer Institute, Bethesda, MD, United States
Guidelines On Kaposi's Sarcoma Treatment: Results From Two Cochrane Systematic Reviews
Esther E. Freeman
Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States
Kaposi Sarcoma in the Era of Combination Antiretroviral Therapy
Matthias Egger
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Randomized Trial of Protease Inhibitor-Based Antiretroviral Therapy for Kaposi Sarcoma in Africa
Jeffrey Martin
University of California San Francisco, San Francisco, CA, United States
The Effect of Protease Inhibitor Use On Kaposi Sarcoma Incidence in a cART-Experienced Cohort
Elizabeth Chiao
Baylor College of Medicine, Houston, TX, United States
Indoleamine 2,3-Dioxygenase (IDO) Activity as a Determinant of Kaposi Sarcoma in Africa
Helen Byakwaga
University of California San Francisco, San Francisco, CA, United States and Mbarara University of Science and Technology, Mbarara, Uganda
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
7 of
7
|
